Fintel reports that on February 27, 2025, HC Wainwright & Co. downgraded their outlook for LAVA Therapeutics N.V.

HC Wainwright upgraded shares of Arcus Biosciences (NYSE:RCUS – Free Report) from a neutral rating to a buy rating in a research note issued to investors on Wednesday, Marketbeat.com reports. The firm ...

HC Wainwright reissued their neutral rating on shares of CECO Environmental (NASDAQ:CECO – Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. HC Wainwright also ...

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.

H.C. Wainwright downgraded Geron (GERN) to Neutral from Buy without a price target following the Q4 report. The shift in guidance for interim ...

Fintel reports that on February 24, 2025, HC Wainwright & Co. initiated coverage of Veritone (LSE:0LP5) with a Buy recommendation. As of January 29, 2025, the average one-year price target for ...

Pemgarda has a standing emergency use authorization as a prophylaxis for immunocompromised patients, but FDA’s stringent ...

Highlights,Adjusted Q1 2025 EPS projections for Bausch + Lomb as analysts slightly reduce expectations.,Diverse analyst ...

H.C. Wainwright raised the firm’s price target on Hive Digital (HIVE) to $10 from $8 and keeps a Buy rating on the shares. The company reported ...

Fintel reports that on February 26, 2025, HC Wainwright & Co. upgraded their outlook for Arcus Biosciences (NYSE:RCUS) from ...

Fintel reports that on February 24, 2025, HC Wainwright & Co. initiated coverage of Veritone (NasdaqGM:VERI) with a Buy recommendation. As of February 19, 2025, the average one-year price target ...